...
首页> 外文期刊>Mini reviews in medicinal chemistry >Main Anti-tumor Angiogenesis Agents Isolated From Chinese Herbal Medicines
【24h】

Main Anti-tumor Angiogenesis Agents Isolated From Chinese Herbal Medicines

机译:从中草药中分离出的主要抗肿瘤血管生成剂

获取原文
获取原文并翻译 | 示例
           

摘要

With a long history of clinical use, Chinese herbal medicine (CHM) is emerging as a noticeable choice for its multi-level, multi-target and coordinated intervention effects against tumor. Recently, many agents from CHM have shown powerful anti-angiogenic activities against tumor. In this review, we discussed the anti-tumor angiogenic activities of 6 kinds of agents from CHM (sulfated polysaccharides/glycopeptides, flavonoids, artemisinin, arsenic trioxide, ginsenoside, and tanshinone). The underlying pharmacological mechanisms of cancer angiogenesis inhibition by these agents are also gradually shown to us. Sulfated polysaccharides/glycopeptides and flavonoids may have synergistic effects with targeted anti-angiogenic drugs mainly targeting VEGF pathway by inhibiting bFGF and HIF-1 alpha pathway, respectively. It is interesting that artemisinin and arsenic trioxide, two famous natural products worldwide, also have antitumor activity at least in part via angiogenesis inhibition. In addition, some natural products that are widely used for patients with cancer, such as ginseng and danshen, act as double-edged swords for tumor angiogenesis. Our review is aimed at providing an understanding of anti-angiogenic compounds from CHM and we propose that these breakthrough findings may have important implications for targeted-angiogenesis therapy and modernization of CHM.
机译:具有悠久的临床使用历史,中草药(CHM)因其对肿瘤的多层次,多目标和协同干预作用而成为一种引人注目的选择。最近,来自CHM的许多药物已显示出强大的抗肿瘤血管生成活性。在这篇综述中,我们讨论了CHM的6种药物(硫酸化多糖/糖肽,类黄酮,青蒿素,三氧化二砷,人参皂甙和丹参酮)的抗肿瘤血管生成活性。这些试剂抑制癌症血管生成的潜在药理机制也逐渐向我们展示。硫酸化多糖/糖肽和类黄酮可能与分别通过抑制bFGF和HIF-1α途径分别靶向VEGF途径的靶向抗血管生成药物具有协同作用。有趣的是,青蒿素和三氧化二砷(全世界两个著名的天然产物)也至少部分通过抑制血管生成而具有抗肿瘤活性。此外,人参和丹参等一些广泛用于癌症患者的天然产品,充当了肿瘤血管生成的双刃剑。我们的综述旨在提供对CHM的抗血管生成化合物的理解,我们建议这些突破性发现可能对靶向血管生成疗法和CHM现代化具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号